1. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement;Kim;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2017
2. Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO–friends of cancer research joint research statement;Kim;Clin. Cancer Res.,2021
3. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015;Jin;J. Clin. Oncol.,2017
4. Modernizing eligibility criteria for molecularly driven trials;Kim;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2015
5. U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies, US Food Drug Adm, 2020. 〈https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent〉.